Nuveen Asset Management, LLC Revance Therapeutics, Inc. Transaction History
Nuveen Asset Management, LLC
- $340 Billion
- Q4 2024
A detailed history of Nuveen Asset Management, LLC transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 423,189 shares of RVNC stock, worth $1.09 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
423,189
Previous 455,313
7.06%
Holding current value
$1.09 Million
Previous $1.17 Million
7.09%
% of portfolio
0.0%
Previous 0.0%
Shares
24 transactions
Others Institutions Holding RVNC
# of Institutions
33Shares Held
10.6MCall Options Held
370KPut Options Held
0-
Black Rock Inc. New York, NY8.57MShares$22 Million0.0% of portfolio
-
Rothschild & CO Asset Management Us Inc. New York, NY370KShares$949,9950.1% of portfolio
-
International Biotechnology Trust PLC London, X0289KShares$742,0251.12% of portfolio
-
Ubs Asset Management Americas Inc Chicago, IL237KShares$610,1410.0% of portfolio
-
Credit Suisse Ag Zurich, V8180KShares$462,9800.0% of portfolio
About Revance Therapeutics, Inc.
- Ticker RVNC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 82,305,696
- Market Cap $212M
- Description
- Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...